GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Debt-to-Asset

OSE Immunotherapeutics (XPAR:OSE) Debt-to-Asset : 0.56 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics Debt-to-Asset?

OSE Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €7.26 Mil. OSE Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €38.54 Mil. OSE Immunotherapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €82.05 Mil. OSE Immunotherapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.56.


OSE Immunotherapeutics Debt-to-Asset Historical Data

The historical data trend for OSE Immunotherapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics Debt-to-Asset Chart

OSE Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.20 0.37 0.49 0.56

OSE Immunotherapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.35 0.49 0.54 0.56

Competitive Comparison of OSE Immunotherapeutics's Debt-to-Asset

For the Biotechnology subindustry, OSE Immunotherapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OSE Immunotherapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Debt-to-Asset falls into.



OSE Immunotherapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

OSE Immunotherapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(7.261 + 38.541) / 82.054
=0.56

OSE Immunotherapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(7.261 + 38.541) / 82.054
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OSE Immunotherapeutics  (XPAR:OSE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


OSE Immunotherapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


OSE Immunotherapeutics (XPAR:OSE) Business Description

Traded in Other Exchanges
Address
22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines